Patents by Inventor Niels P. Ryde

Niels P. Ryde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reduction of flake-like aggregation in nanoparticulate active agent compositions
    Patent number: 11717481
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: August 8, 2023
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
    Publication number: 20220211626
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: December 3, 2021
    Publication date: July 7, 2022
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Reduction of flake-like aggregation in nanoparticulate active agent compositions
    Patent number: 11253478
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 22, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
    Publication number: 20180250229
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Reduction of flake-like aggregation in nanoparticulate active agent compositions
    Patent number: 9974748
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 22, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Reduction of flake-like aggregation in nanoparticulate active agent compositions
    Patent number: 9974746
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 22, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Reduction of flake-like aggregation in nanoparticulate active agent compositions
    Patent number: 9974747
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 22, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
    Publication number: 20160228372
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
    Publication number: 20160228554
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
    Publication number: 20160228555
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Reduction of flake-like aggregation in nanoparticulate active agent compositions
    Patent number: 9345665
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: May 24, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
    Publication number: 20140234225
    Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.
    Type: Application
    Filed: February 17, 2014
    Publication date: August 21, 2014
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Christian F. Wertz, Niels P. Ryde
  • REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
    Publication number: 20140105984
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer
    Patent number: 8652464
    Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: February 18, 2014
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Christian F. Wertz, Niels P. Ryde
  • LOW VISCOSITY LIQUID DOSAGE FORMS
    Publication number: 20130251805
    Abstract: The present invention relates to liquid dosage forms of nanoparticulate active agents having very low viscosities.
    Type: Application
    Filed: December 7, 2012
    Publication date: September 26, 2013
    Applicant: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Tuula RYDE, Niels P. Ryde, H. William Bosch, John D. Pruitt, Christian F. Wertz
  • Nanoparticulate compositions having lysozyme as a surface stabilizer
    Patent number: 8323641
    Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: December 4, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Christian F. Wertz, Niels P. Ryde
  • In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
    Patent number: 8309136
    Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: November 13, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
  • Glipizide compositions
    Patent number: 8236352
    Abstract: The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: August 7, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: H. William Bosch, Niels P. Ryde, Rajeev A. Jain, Jon Swanson, Robert Hontz, John G. Devane, Kenneth Ian Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
    Patent number: 7998507
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: August 16, 2011
    Assignee: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Greta G. Cary, Douglas C. Hovey, Rajeev A. Jain, Laura J. Kline, Elaine Merisko-Liversidge, Kevin D. Ostrander, Niels P. Ryde, Stephen B. Ruddy
  • LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
    Publication number: 20110165251
    Abstract: The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.
    Type: Application
    Filed: March 9, 2011
    Publication date: July 7, 2011
    Inventors: H. William BOSCH, Matthew R. HILBORN, Douglas C. HOVEY, Laura J. KLINE, Robert W. LEE, John D. PRUITT, Niels P. RYDE, Tuula A. RYDE, Shuqian XU